T1	intervention 51 82	peripherally inserted catheters
T2	control 90 114	implanted port catheters
T3	eligibility 147 180	patients with early breast cancer
T4	outcome-Measure 646 794	identify which device has a lower probability of catheter-related significant adverse events (CR-SAEs) within the 35 weeks after device implantation
T7	total-participants 916 919	256
T8	total-participants 948 951	253
T9	outcome 1014 1021	CR-SAEs
T10	outcome 1107 1144	probability that a CR-SAE would occur
T11	iv-bin-percent 1149 1153	7.8%
T12	iv-bin-abs 1155 1157	10
T13	cv-bin-percent 1184 1189	16.6%
T14	cv-bin-abs 1191 1193	21
T15	outcome 1332 1347	risk of CR-SAEs
T6	outcome 1461 1464	QoL
T16	outcome 1507 1517	discomfort
T17	outcome 1678 1685	CR-SAEs
T5	outcome-Measure 836 857	quality of life (QoL)
T18	outcome-Measure 862 882	patient satisfaction
